Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?
Published . Updated .
Krystal Biotech (KRYS) just paired a third quarter earnings beat with a new US$400 million share repurchase plan, giving investors fresh numbers on Vyjuvek demand and updated signals on management’s capital priorities. Despite the earnings beat and buyback announcement, Krystal
Directly affected
- KRYS Krystal Biotech+1.5% 19d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- PFE Pfizer+8.9% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- MRK Merck+4.0% 17d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| KRYS | +8.27% | +9.57% | base | after close | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| XBINo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth? Yahoo Finance
Source: Yahoo Finance
The price since 3 Nov 2026: Select Sector Spdr Tr (XLV) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| KRYS | three days earlier | +9.57% | final price |
| KRYS | five days earlier | +8.27% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
For “Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- XBI Spdr Series Trust
In “Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- LLY Eli Lilly
In “Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- JNJ Johnson & Johnson
For “Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- PFE Pfizer
For “Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- MRK Merck
In “Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
“Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?” (3 Nov 2026) reaches Select Sector Spdr Tr (XLV) through this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1415.62.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.